{{Rsnum
|rsid=41557318
|Gene=CBR1
|Chromosome=21
|position=36071051
|Orientation=plus
|GMAF=0.001377
|Gene_s=CBR1,DNAJC18
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{PharmGKB
|RSID=rs41557318
|Name_s=CBR1:Pro131Ser; P131S
|Gene_s=CBR1, SETD4
|Feature=
|Evidence=PubMed ID:19204081
|Annotation=Risk or phenotype-associated allele: T Phenotype: Kinetic studies using purified, histidine-tagged, recombinant enzymes demonstrated that the P131S mutation leads to decreased catalytic efficiency (Kcat/Km) for doxorubicin and daunorubicin compared to wild type protein. Type of association: FA
|Drugs=daunorubicin; doxorubicin
|Drug Classes=ANTHRACYCLINES AND RELATED SUBSTANCES
|Diseases=Breast Neoplasms; Cardiomyopathies; Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165291530
}}

{{PMID Auto
|PMID=19022938
|Title=Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}